| Strategies |
Incremental cost-effectiveness ratio
(US$/years of life saved) |
| Cost of vaccination |
US$25 |
US$50 |
US$75 |
US$100 |
US$450 |
Risk reduction (%) |
| Pap test (3x) |
inferior |
inferior |
inferior |
inferior |
inferior |
21.9 |
| HPV-DNA test (3x) |
inferior |
inferior |
500 |
500 |
500 |
30.7 |
| Vaccine |
superior |
300 |
inferior |
inferior |
inferior |
42.7 |
| Vaccine + Pap test (3x) |
200 |
inferior |
inferior |
inferior |
inferior |
55.6 |
| Vaccine + HPV test (3x) |
700 |
1,000 |
1,100 |
1,700 |
9,600 |
60.8 |
Inferior: more costly and less effective than the alternative strategy; Superior: more effective and less costly than the alternative strategy; Pap 3x: Papanicolaou test
performed at 35, 40 and 45 years; HPV-DNA: hybrid capture test performed at 35, 40 and 45 years; Vaccine: vaccination of pre-adolescent girls between 9 and 12 years old |
